BNET Industries
Market Cap:$346.5K
Last Fiscal Year Sales:$2.2M
- Public
- US
Dow Jones Description
Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics' product development pipeline includes: the FDA cleared-to-market NeuroPort? System, a neural monitor designed for acute inpatient applications and labeled for temporary (less than 30 days) recording and monitoring of brain electrical activity; the Andara? Oscillating Field Stimulator? (OFS) Device, an investigative device designed to stimulate regeneration of the neural tissue surrounding the spinal cord; and the BrainGate System, an investigative device designed to provide communication and control of a computer, assistive devices, and, ultimately, limb movement.
Founder and Chief Scientific Officer
John P. DonoghueContact Information
100 Foxborough Boulevard
Suite 240
Foxborough, Massachusetts 02035
508-549-9981
Peer Companies
NAICS Code Research and Development in the Social Sciences and Humanities: 541720
News & Analysis
Filter by
cyberkinetics neurotechnology systems inc. and fda - All News and Analysis
Investor Update.
- 2007-06-12
M2 PRESSWIRE-12 June 2007-Businessnetwire.us: Investor UpdateC1994-2007 M2 COMMUNICATIONS LTD RDATE:12062007 New York, NY -- BusinessNetWire's "Investor's Update" Focuses on the Following Companies: COMMERCE PLANET, INC. (OTCBB: CPNE); BIOVEST INTERNATIONAL, INC. (OTCBB: BVTI); ODYNE CORPORATION (OTCBB: ODYC); CYBERKINETICS ...
Richard Borgens, Ph.D., and Purdue Researchers Report Progress on Program Licensed to Cyberkinetics Neurotechnology Systems, Inc.; Compound May Prevent Neural Cell Death
- 2006-04-17
FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN: "Cyberkinetics") announced that the Journal of Neuroscience published two studies conducted by research teams at Purdue University's Center for Paralysis Research concerning technology licensed to Cyberkinetics. Together, the studies indicate that hydralazine, already approved for other uses by the FDA, and certain...
ALS Patients Offered Access to Cyberkinetics' BrainGate™ System in New Pilot Study at Massachusetts General Hospital
- 2005-08-22
FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN) Cyberkinetics today announced the start of a new pilot clinical study of the BrainGateTM Neural Interface System, a brain-computer interface BCI, in individuals diagnosed with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) or other progressive motor neuron diseases. Cyberkinetics received regulatory...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| John P. Donoghue | Founder and Chief Scientific Officer |
| Kurt H. Kruger | CFO |
| J. Christophe Flaherty | Executive Vice President, Technology and Intellectual Property |
| Mark A. Carney | Executive Vice President |
| Kimi E. Iguchi | Vice President, Finance |
| Mark P Carthy |
| Organization | Position | Status |
|---|---|---|
| Oxford Bioscience Partners | Chief Scientific Officer, Director | Current |
| Cyberkinetics Neurotechnology Systems, Inc. | Founder and Chief Scientific Officer | Current |
| Cyberkinetics Neurotechnology Systems, Inc. | Board of Directors | Current |
| Brown University | Executive Director | Former |
| Brown University | Ph.D. in Neuroscience | Former |
| University of Vermont | M.S. in Anatomy | Former |
| Boston University | A.B. | Former |
| Organization | Position | Status |
|---|---|---|
| Cyberkinetics Neurotechnology Systems, Inc. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Cyberkinetics Neurotechnology Systems, Inc. | Executive Vice President, Technology and Intellectual Property | Current |
| Viasys Healthcare Inc. | Vice President of Engineering and New Technologies | Former |
| Biogen Idec, Inc. | Senior Manager of External Reporting | Former |
| Massachusetts Institute of Technology | B.S. in Aeronautical and Electrical Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Cyberkinetics Neurotechnology Systems, Inc. | Executive Vice President | Current |
| Cyberkinetics Neurotechnology Systems, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Cyberkinetics Neurotechnology Systems, Inc. | Vice President, Finance | Current |
| Global Life Science Ventures AG | Vice President, Finance | Current |
| Oxford Bioscience Partners | Vice President, Finance | Current |
| Millennium Pharmaceuticals, Inc. | Senior Director | Former |
| Continental Cablevision | Director of Financial Reporting | Former |
| PricewaterhouseCoopers | Senior Audit Manager | Former |
| Biogen Idec, Inc. | Senior Manager of External Reporting | Former |
| Biogen, Inc. | Senior Manager | Former |
| Cooper's Inc. | Accountant | Former |
| Northeastern University | M.B.A. | Former |
| Drew University | B.A. In Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Astex Therapeutics Limited | Founder of Orion Healthcare Equities | Current |
| Oxford Bioscience Partners | General Partner | Current |
| Dynogen Pharmaceuticals, Inc. | General Partner, Oxford Bioscience Partners | Current |
| West Membership Co | Venture Partner, Oxford Bioscience Partners | Current |
| Cyberkinetics Neurotechnology Systems, Inc. | Current | |
| Oxford Bioscience Partners | Director | Current |
| Astex Therapeutics Limited | Board of Directors | Current |
| Impactrx, Inc. | Director | Current |
| Xanthus Pharmaceuticals, Inc. | Board of Directors | Current |
| Global Life Science Ventures AG | Board of Directors | Current |
| Scion Pharmaceuticals, Inc. | Director | Current |
| Xanthus, Inc. | Board of Directors | Current |
| Solexa, Inc. | Director | Current |
| Salix Pharmaceuticals, Inc. | Investor | Current |
| Cubist Pharmaceuticals, Inc. | Chief Business Officer | Former |
| Vertex Pharmaceuticals Incorporated | Senior Director of Business Development | Former |
| Dendreon Corporation | Director | Former |
| Ensemble, LLC | Investor | Former |
| Xanthus, Inc. | Investor | Former |
| Solexa, Inc. | Investor | Former |
| Impactrx, Inc. | Investor | Former |
| Harvard Business School | Mba | Former |
| University of Missouri | M.S. In Chemical Engineering | Former |
| University College Dublin | B.E. In Chemical Engineering | Former |
Industry Transcripts by Seeking Alpha
-
Casella Waste Systems Inc. F2Q10 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 03, 2009about CWST
-
51jobs Q3 2009 Earnings Call Transcript
on Nov 23, 2009about JOBS
-
NetEase Q3 2009 Earnings Call Transcript
on Nov 18, 2009about NTES
-
Franklin Covey Co. F4Q09 (Qtr End 08/31/09) Earnings Call Transcript
on Nov 16, 2009about FC
-
Cellcom Israel Ltd. Q3 2009 Earnings Call Transcript
on Nov 16, 2009about CEL
IndustryTop Rated
